Bal Pharma Limited — Important, 24-02-2025: Updates

**Updates:**

Bal Pharma Limited has resubmitted its unaudited financial results for the quarter ended December 31, 2024. Revenue from operations for the quarter stood at ₹7,288.52 Cr, a decrease from ₹8,149.46 Cr during the same quarter last year. Total income for the period was ₹7,370.49 Cr, reflecting a decline compared to ₹8,175.17 Cr in the previous year. The company reported a net profit of ₹115.58 Cr, slightly lower than ₹125.71 Cr in Q3 FY24. Operational expenses totaled ₹7,250.06 Cr. The overall results suggest ongoing challenges in revenue generation, warranting close observation of the company's recovery strategies and market performance moving forward.

**Investor Presentation:**

1. **Financial Highlights:** Q3 revenue declined to ₹7,288.52 Cr from ₹8,149.46 Cr YoY, while net profit was ₹115.58 Cr, a modest decline from ₹125.71 Cr last year. Total income was ₹7,370.49 Cr.

2. **Strategic Initiatives and Growth Drivers:** Management indicated continuous efforts to enhance operational efficiency and maintain market presence amidst challenging conditions.

3. **Business Developments:** The company is strategizing on revamping its portfolio and marketing efforts to boost performance, particularly given the performance of its subsidiaries.

4. **Market Position and Competitive Advantage:** Despite the revenue decline, the company remains a significant player in the pharmaceuticals sector, focused on regaining its market traction.

5. **Investor Implications:** Investors should monitor the company's strategic initiatives and quarterly performance closely, as these will dictate short- to medium-term growth prospects.

**Company Announcements:**

Bal Pharma has declared an unmodified opinion from its statutory auditors on the unaudited financial results for the quarter ending December 31, 2024, underscoring the adherence to accounting standards and the integrity of the financial reports presented. The results were approved by the Board of Directors and reflect the company's ongoing commitment to transparency.